Presented by: University of Kentucky Department of Pathology
“Rare Lesions of the Breast”
Omar A. Abdelsadek, MD
Faculty Candidate for Clinical Chemistry
Multidisciplinary Breast Pathology Fellow
Mayo Clinic
Monday, November 10, 2025
12:00 – 1:00pm
In-Person MS 147 or Zoom: http://us06web.zoom.us/j/89110280273? pwd=ybybn06jFDKtJzTCALTtz15lG8vhKV.1We
PASSCODE: 281106
Use the QR code to register for this Grand Rounds if you have not already registered.
At the completion of this lecture attendees should be able to:
- Clarify historical evolution
- Identify histological patterns and immunophenotype
Distinguish diagnostic pitfalls and mimics
- Compare WHO vs other classifications
- Report prognosis: benign/atypical/malignant
Disclosure of Financial Interest Summary to Learners
All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.
None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speake rs will inform the audience when they are discussing investigational and/or off-label uses.
Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
- 1.00 AMA PRA Category 1 Credit™
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
- 1.00 ParticipationUK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.

Facebook
X
LinkedIn
Forward